All News
Giant Cell Arteritis Novel Treatment Options
Giant cell arteritis is associated with significant treatment related morbidity due to the dependence on glucocorticoids as a treatment option. After sixty years of therapeutic stagnation, these are exciting times in the management of GCA. At this year's ACR Convergence meeting, encouraging data will be presented on options for GCA.
Read Article
Top vasculitis takeaways from ACR 2021
There were several hot topics at ACR21. Here I concentrate on top abstracts in vasculitis.
Read Article
Day 4 Report from ACR21
My favorite three presentations from day 4 (Tuesday) at ACR 2021 included the following.
Read Article
NEJM Clinical Images - Tongue Necrosis in Giant Cell Arteritis. 74-yoF w/ 3-day hx of HA and tongue swelling/pain, & blindness in the right eye. Tongue was ulcerated, R temporal artery thickened. ESR 42 CRP 169 mg/L. Read rest of story... https://t.co/DDgu0UpZN9 https://t.co/BPlIEmRjg3
Links:
Dr. John Cush RheumNow ( View Tweet)
Genes and Obesity Tied to Higher Gout Risk in Women
Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.
https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Giant Cell Arteritis Novel Treatment Options
https://t.co/ywqGZNmHOa https://t.co/2hLESL1RjO
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica
Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting.
https://t.co/UN66qOGqRd
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Session Review: Dr. Arthur Kavanaugh discussed the FDA session presented at the ACR21meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.
https://t.co/5YkbzDv0YR https://t.co/MS9KNIfm2m
Links:
Dr. John Cush RheumNow ( View Tweet)
COVID-19 in Patients with Primary Systemic Vasculitis and Polymyalgia Rheumatica
Dr. Bella Mehta ( @bella_mehta) interviews Dr. Sebastian Sattui about abstract #0952 presented at the #ACR21 annual meeting.
https://t.co/BYyz0Xj1Fj
Links:
Dr. John Cush RheumNow ( View Tweet)
In case you missed it…
Watch: What's Cool and Hot in Vasculitis with Dr. Janet Pope (@Janetbirdope ) #ACR21
https://t.co/JbhQWeejy7 https://t.co/qlCCk3MXKu
Links:
Dr. John Cush RheumNow ( View Tweet)
📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis
#ACR21 https://t.co/Bdz5t2uyHi
Guy Katz, MD GuyKatzMD ( View Tweet)
#ACR21 #ACR2021 Clinical Pearls
🚨 Thread Alert
1/n
💥AAV does not typically cause hard palate lesions➡️consider:
Cocaine induced midline destructive lesion(HNE+)/Malignancy
💥Limited GPA can be ANCA negetive in 50%
💥 oral cavity examination is a must in Rheum https://t.co/RxkLiGdcJt
EnvisionRheumat ERheumat ( View Tweet)
#ACR21 TM24. Hydralazine-induced ANCA vasculitis presenting with chondritis.
Labs:
+ANA
+Anti-histone
+p-ANCA, +MPO and +PR3
@Rheumnow https://t.co/YQvqj0vCHp https://t.co/LPyVYYzLtI
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 2022 ACR/EULAR GPA Criteria
▶️Classification, NOT diagnostic!
⭐️Clinical, lab, imaging, and biopsy criteria
⭐️+5 pts for cANCA or PR3, negative pts for pANCA or MPO, or eosinophilia
@RheumNow https://t.co/6YWmabNzuH https://t.co/vg8zaFt5dR
Links:
Eric Dein ericdeinmd ( View Tweet)
ACR/EULAR Classification Criteria for ANCA vasculitis, updated from prior
Similar disclaimer; these are for use AFTER the diagnosis of small or medium vasculitis has been made
Great international effort, kudos to all involved
#ACR21 #ACRambassador https://t.co/a29TVvzVF7
Mike Putman EBRheum ( View Tweet)
#ACR21
new 2022 classification criteria by ACR/EULAR for AAV
💥GPA-Sensitivity-92%, Specificity-94%
💥MPA-Sensitivity-91%, Specificity-94%
💥EGPA-Sensitivity-85%, Specificity-99%
💥Score based https://t.co/61SOl4Tovg
EnvisionRheumat ERheumat ( View Tweet)
What's Cool and Hot in Vasculitis: Dr. Janet Pope reviews abstracts #0505, #0466, #0430, #0507 and #0504, being presented at the #ACR21 annual meeting.
https://t.co/7XwjFuJEMM https://t.co/BC9wjPzNC0
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR21 2022 ACR/EULAR MPA Criteria
▶️Classification, NOT diagnostic!
⭐️Clinical: negative for nasal GPA symptoms
⭐️Lab: +6 for pANCA or MPO, negative for cANCA/PR3 or eosinophilia
@RheumNow https://t.co/6YWmabNzuH https://t.co/XVzBF2KONp
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 2022 ACR/EULAR Large Vessel Vasculitis Criteria:
🌎One reason for updating 31 year old criteria -> now an international effort that better reflects heterogeneous global disease
@RheumNow https://t.co/6YWmabNzuH https://t.co/YXm85uQZCK
Links:
Eric Dein ericdeinmd ( View Tweet)
ACR/EULAR Classification Criteria for Large Vessel Vasculitis (TAK/GCA), updated from prior to include imaging
Must emphasize typical disclaimers; these are for classification, not specifically for diagnosis
Great effort and useful result, esp for trials
#ACR21 @petercgrayson https://t.co/IYFyh5oYBT
Mike Putman EBRheum ( View Tweet)
